Audentes plans gene therapy facility in NC

By The Science Advisory Board staff writers

Audentes Therapeutics has announced that it plans to invest $109 million to build a new 135,00-sq-ft gene therapy manufacturing facility in Sanford, NC, that is expected to be operational by 2021.

The fundraising phase of the project will take approximately 18 months and the remaining investment will take place over two additional planned expansion phases.

Architectural rendering of Audentes Therapeutics new gene therapy manufacturing facility planned in Sanford, NC.
Architectural rendering of Audentes Therapeutics new gene therapy manufacturing facility planned in Sanford, NC. Image courtesy of Audentes Therapeutics.

Audentes, a subsidiary of pharmaceutical developer Astellas Pharma, focuses on developing adeno associated virus (AAV)-based genetic medicines. Its extensive gene therapy portfolio targets rare neuromuscular diseases. The company uses its AAV gene therapy platform and manufacturing expertise in three areas: gene replacement, vectorized exon skipping, and vectorized RNA knockdown.

The North Carolina Department of Commerce, along with other partners, led the state's support for the company's decision to build. The facility will create over 200 new jobs in Lee County in North Carolina.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?